Marina Biotech acquires RNAi delivery technology

Marina Biotech of Bothell, WA, has added more siRNA IP to its toybox by acquiring the rights to technology from Germany's Novosom in exchange for $5 million in common stock. 

Development of gene-silencing RNA therapeutics has been delayed for years because of difficulties in finding a delivery device that can slip inside a cell, precisely deliver the therapeutics, then go away harmlessly.

In-PharmaTechnologist reports that Novosom has applied its technology to the delivery of antisense, siRNA, LNA and other oligonucleotides. The technology, called "Smarticles," involves liposomes that can cross cell membranes to deliver to the target and engage the RNA interference pathway. It can also change its surface electric charge to drop off its payload.

- see the Marina Biotech release
- read the in-PharmaTechnologist report
- a more technical description can be found on the RNAi therapeutics blog

Suggested Articles

Kala Pharma's Eysuvis on Tuesday became the first and only corticosteroid approved to treat short-term signs and symptoms of dry eye disease.

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.